| INTRODUCTION
Gastrointestinal symptoms account for a significant percentage of doctor visits in primary care. 1, 2 For approximately one third of these symptoms, no structural, organic, systemic or metabolic cause can be found during routine diagnostic procedures. 2, 3 These patients are classified as having a functional gastrointestinal disorder (FGID). One of the most common FGIDs is functional dyspepsia (FD), a disorder of the upper GI tract affecting 5%-20% of the population worldwide. [3] [4] [5] FD is characterised by recurrent or chronic epigastric symptoms, including early satiation, postprandial fullness, epigastric pain and epigastric burning.
The Rome IV consensus established that symptoms have to be severe enough to interfere with usual activities and occur at least 3 days per week over the last 3 months for early satiation and postprandial fullness and 1 day per week for epigastric pain or burning, with symptom onset at least 6 months prior to diagnosis. 2, 6 FD can be subdivided into two subgroups: epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). The EPS subgroup is characterised by meal-unrelated symptoms, such as epigastric pain and epigastric burning, whereas the PDS subtype is defined by symptoms triggered or aggravated by a meal, including postprandial fullness and early satiation. 7 Different pathophysiological mechanisms are considered to underlie the two distinct subtypes.
Visceral hypersensitivity is proposed to be the main underlying mechanism in the EPS subgroup, while disturbed GI motility, including impaired gastric accommodation to a meal and delayed gastric emptying, are suggested to play a role in symptom development in the PDS subgroup. 8 In addition, dysfunction of the brain-gut-axis is considered an important determinant of symptom intensity perception in both subgroups. 8, 9 Although FD is not life threatening, it impairs quality of life, has a significant negative impact on work productivity, and increases health care expenses for both the patients and society. 7 Nevertheless, there is no standard satisfactory pharmacological treatment available for these patients, and research often shows conflicting results. In the last decades, the interest in nonpharmacological treatment options for FD increased, partly because of the absence of efficient pharmacological treatment options.
This review was conducted to provide an overview of all current pharmacological and nonpharmacological treatment options for FD, their efficacy and their limitations(including side effects). Furthermore, we aim to highlight the remaining questions and concerns in relation to FD treatment. A literature search was performed in
Pubmed to identify relevant trials.
| MATERIALS AND METHODS
A search was performed to identify relevant full text articles in English on Pubmed, and on published abstracts of relevant recent conferences. Used keywords included "acid suppressive therapy,"
"prokinetic agent," "H pylori," "phytotherapy," "peppermint oil," "ginger," "Rikkunshito," "iberogast," "STW5," "acupuncture,"
"psychotherapy," "behavioural therapy," "hypnotherapy" and "cognitive therapy" in combination with "functional dyspepsia". Furthermore, specific drug names were used as search item in Pubmed to identify related articles. An additional search of bibliographies of the included articles was performed to identify studies that were not detected in the initial search.
| CURRENT TREATMENT OPTIONS FOR
FUNCTIONAL D YSPEPSIA
| Helicobacter pylori eradication
At least 50% of the world's population is infected with Helicobacter pylori (H pylori), with variable prevalence in different parts of the world. 10, 11 In FD patients, the prevalence of H. pylori infection is stated to be between 40% and 70%. 12 The exact role of H pylori infection in the development of FD symptoms and remains controversial, with conflicting results yielded from several clinical studies. Of the 22 randomised trials identified for this review, 9 reported a significant stronger symptom improvement after H pylori eradication, commonly consisting of a proton pump inhibitor combined with an antibiotic, in comparison with placebo or control therapies, [11] [12] [13] [14] [15] [16] [17] [18] [19] whereas 13 studies failed to find convincing results for the superiority of eradication therapy over placebo therapy to relief FD symptoms (Table 1) . [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Two studies showed that H pylori eradication is more effective in the EPS subgroup compared to PDS. 13, 17 However, other trials failed to find a significant difference between FD subgroups. Nevertheless, H pylori infection has been shown to be more prevalent in FD patients and a subset of patients respond to eradication with symptomatic benefit.
Consequently, at least in a subset of dyspepsia patients, epigastric symptoms can be attributed to an infection with H pylori. Based on this assumption, the Kyoto consensus proposed the term "Helicobacter-associated dyspepsia" for H pylori-infected patients with FD symptoms, who experience sustained symptomatic benefit from eradication. 33 Furthermore, for this reason, and because the response to eradication is likely to be permanent, eradication of H pylori is recommended as first-line therapy in FD patients who are infected ( Figure 1 ). 5 A recent meta-analysis of 23 studies reported that eradication therapy provides significant symptomatic benefits in the long term (>6 months), but not on the short term (<6 months). Furthermore, the analysis showed that FD patients are more likely to experience side effects, such as diarrhoea, of eradication therapy compared to nonsymptomatic controls. 34 The effects of eradication therapy on gastric function are incompletely elucidated. | 1135 Moreover, PPIs were shown to be more efficacious than prokinetic agents for improving global FD symptoms. 47 These conflicting results highlight the controversy of the suggestion that different symptomatic FD subgroups request distinct therapies. Furthermore, it emphasises the complexity of FD, its underlying pathophysiology, and its treatment.
T A B L E 1 Efficacy and reported (serious) adverse events ((S)AEs)/adverse reactions (ARs) of H. pylori eradication therapy to treat FD
The use of acid suppressants is considered safe, with very few reported adverse events during short-term usage (Table 2) . However, chronic acid suppression may lead to bacterial overgrowth, facilitate the occurrence of enteric infection or gastritis, and delay gastric emptying of a solid meal. 48, 49 As impaired gastric emptying, present in up to 30% of the patients, may be implicated in symptom generation in FD, this is considered an undesirable side effect.
| Prokinetic agents
PDS is considered to be associated with abnormalities of gastric motility, including delayed gastric emptying and impaired gastric accommodation to a meal. Consequently, PDS patients are often treated with prokinetic agents in order to restore disordered motility ( Figure 1) . A meta-analysis of 38 studies showed that prokinetic agents are significantly more effective than placebo in reducing FD symptoms, with a 14% margin over placebo. 50 However, the relation between symptom improvement and improvement of GI motor functions, such as gastric emptying, remains controversial. 51 To date, several classes of prokinetic agents with different mechanisms of action have been developed. The first D 2 -receptor antagonist used for the treatment of motility disorders was metoclopramide. This compound is also a 5-HT 4 -receptor agonist, which may contribute to its prokinetic actions. Metoclopramide readily crosses the blood-brain-barrier, which underlies the potentially irreversible, neurological side effects that may occur with (chronic) metoclopramide intake. Consequently, the drug has received a black box warning due to induction of extrapyramidal symptoms. 52 This might explain the low number of publications on metoclopramide in FD (Table 3) . Four trials comparing the efficacy of metoclopramide with placebo or other drug therapies in FD showed a significant improvement of dyspepsia symptoms after metoclopramide. [53] [54] [55] [56] Furthermore, a recent meta-analysis comparing metoclopramide, trimebutine, mosapride, domperidone, itopride and acotiamide, all prokinetic agents, in 4473 FD patients reported better therapeutic efficacy for metoclopramide compared to itopride and acotiamide. Although no significant differences in efficacy were found between metoclopramide, trimebutine, mosapride and domperidone, metoclopramide showed the best SUCRA probability, which reflects the probability of a treatment being the best in an indirect comparison. 57 Regarding its mechanism of action, metoclopramide has been shown to improve upper GI symptoms, accelerate gastric emptying rate and increase gastrointestinal motility. [52] [53] [54] 58 Whether the effects of metoclopramide differ between the FD subgroups have never been investigated. (Table 3) . 59 , 60 Arts et al reported a reduction in dyspepsia symptoms of up to 76% compared to 16% with placebo. 61 Furthermore, domperidone and metoclopramide were shown to have a similar efficacy.
However, domperidone is less prone to induce side effects and therefore considered to be better tolerated than metoclopramide. 56, 57, 62 Whether domperidone is more effective in one of both FD subgroups has not been investigated. The effect of domperidone on gastric emptying remains controversial, with three of five studies showing no effect, 59, 63, 64 and two reporting an increase in gastric emptying rate. 60, 65 A recent study showed that the therapeutic effect of domperidone is moderated by polymorphisms of the dopamine D 2 -receptor Taql gene. 66 In Europe, domperidone has long been available as an over the counter drug, but, based on recent concerns over its cardiac safety, including a risk for prolongation of the QT-interval and increased risk of ventricular arrhythmia, domperidone is now only available on prescription. 67, 68 In the USA, domperidone has not been approved by the Food and Drug
Administration (FDA) due to these cardiac side effects. 69 However, in the USA, its use can be justified after an Investigational New Drug application for chronic gastrointestinal conditions for which standard therapy failed has been filled out by the prescriber.Other reported side effects of domperidone are hyperprolactinemia and headache. 69, 70 Itopride, available mainly in Asia and to some extent in Eastern Europe, is a commonly used dopamine-2 antagonist for the treatment of FD. In addition to blocking the D 2 -receptor, it inhibits acetylcholinesterase, thereby increasing the levels of acetylcholine, the key neurotransmitter involved in regulating gastric contractility.
Increases in acetylcholine levels promote gastric contractility, enhance lower oesophageal sphincter pressure and accelerate gastric emptying. 71 However, the few mechanistic studies that have been performed with itopride failed to provide evidence for significant effects on gastric emptying, gastric contractility, gastric accommodation and nutrient volume tolerance in healthy subjects and FD patients. 72, 73 Hence, the exact mechanism of action of itopride remains incompletely understood, and symptoms are likely to be improved through other pathways. Further research needs to improve the insight into the mechanism of action of itopride.
To date, research on itopride mainly focused on symptom improvement in FD (Table 3) . Four of six trials identified for this review reported a significant improvement in FD symptoms after 2 to 8 weeks of treatment , 75, 76 whereas two trials observed no improvement compared to placebo. 74, 79 Beneficial effects were seen in a large-scale placebo-controlled phase 2 trial, but were not confirmed in phase 3 trials. Both trials were similar in study design, with 8 weeks of double-blind treatment. However, in the phase 3-trial, positive H Pylori status and symptoms scores lower than 9 on the Leeds Dyspepsia Questionnaire excluded patients from the trial, which was not the case in the phase 2-trial. Therefore, differences in patient selection can explain the discrepancies between both studies.
According to the authors, a large placebo effect due to higher baseline symptom scores in the phase 3 trial can also play a role. Furthermore, the heterogeneity of the disorder can explain these distinct results. 78 , 79 Sawant et al compared the efficacy of itopride and domperidone and reported moderate to complete symptom relief in 81%
of the patients following itopride compared to 70% for domperidone. 75 The superiority over domperidone was confirmed in a metaanalysis of nine itopride trials in FD showing its efficacy in improving postprandial fullness, early satiation and epigastric discomfort, with a stronger effect than domperidone. 71 A recent study evaluating itopride using validated patient-reported outcome measures suggests efficacy of itopride especially in patients with overlapping PDS-EPS. 76 A favourable characteristic of itopride, in comparison to other prokinetic agents such as metoclopramide, is its high polarity, preventing passage through the blood-brain-barrier. Consequently, the use of itopride is not associated with central nervous system-related side effects. 69, 71 A commonly reported adverse event associated with itopride intake is a modest increase in prolactin levels. No reports of itopride-induced prolonged QT-intervals were found. 79 Therefore, itopride can be considered a safe treatment option for FD patients.
Other prokinetic D 2 -receptor antagonists include cinitapride, clebopride and alizapride, but these are less well-investigated in FD.
Studies investigating cinitapride and clebopride reported an improvement of FD symptoms and quality of life. 80, 81 Alizapride is mostly used for its antiemetic properties. 
| Serotonin-4 receptor agonists
Another class of prokinetic agents are the serotonin-4 (5-HT 4 ) receptor agonists, including cisapride, mosapride and tegaserod. 84 Cisapride, developed in the 1990s for the treatment of gastrooesophageal reflux disease, rapidly evolved to become the leading prokinetic drug for treatment of upper gastrointestinal hypomotility disorders. Several studies showed that cisapride improves gastric emptying rate in patients with FD and gastroparesis. 85, 86 Additionally, a study in healthy subjects demonstrated that cisapride enhances gastric accommodation. 87 The effects of cisapride on gastrointestinal symptoms on the other hand, remain debatable, with studies showing no significant differences compared to placebo due to high placebo responses, 88, 89 and others reporting superiority to placebo or to other prokinetic agents with a response rate around 70%. 92, 93 It has been reported that cisapride only improves symptoms in patients with abnormal gastric motility at baseline. 95 In any case, this prokinetic agent has been withdrawn from the market in 2006 because of cardiac safety concerns. 96 Mosapride is available as a prokinetic agent in many Asian countries. Preclinical and clinical studies provided evidence for mosapride as a useful therapy for FD by showing its stimulating effect on gastric emptying, gastric accommodation and gastric motility in rats and healthy subjects. 97, 98 Thus far, no mechanistic studies in FD patients have been performed. Regarding symptom relief, a large-scale randomised comparative Japanese study with mosapride and teprenone, a gastric mucosa-protecting agent, showed that mosapride reduces symptoms of gastric stasis and epigastric pain and improves quality of life of FD patients (Table 3) . Symptom reduction was reported in 91% of the patients after mosapride treatment, compared to 52% for teprenone. 84 A meta-analysis comparing mosapride with dopamine antagonists showed that mosapride had a 6.7% greater probability of producing a symptomatic response in FD patients. 102 However, a European study found no beneficial effect of mosapride over placebo in terms of symptom improvement. 103 This could be explained by differences in study population characteristics, such as ethnicity, and again highlights the heterogeneity of FD. Overall, mosapride is a well-tolerated compound. The main adverse events that have been reported are diarrhoea, headache and dry mouth, all reported in less than 5% of the patients. 104 Lastly, tegaserod, a partial 5-HT 4 agonist that was originally on the market for constipation-predominant IBS and functional constipation, showed to be beneficial in the treatment of FD as well. 105, 106 A large randomised, placebo-controlled study consisting of two identical trials showed a 4.6% improvement in days with satisfactory symptom relief after 6 weeks of tegaserod treatment (6 mg twice a day) over placebo. Although these results were statistically significant, the clinical value is rather small. Of note, the treatment effect was reported to be greater in patients with at least moderate or severe symptoms at baseline. 107 In another study in women with FD who were on PPI treatment for concomitant heartburn, significant symptom relief (69%) was observed after 10 weeks of tegaserod treatment (6 mg twice a day) compared to baseline, but the improvement over placebo was negligible due to the high placebo response (62%). 108 of the patients. 123 The efficacy of acotiamide to reduce FD symptoms is further supported by several other clinical placebo-controlled trials, reporting a response rate between 31% and 78% after two or more weeks of treatment. 116, 117, 120, 123, 124 To date, the available literature on acotiamide contains only one trial that failed to find a significant difference in improvement rates between acotiamide and placebo. However, this study showed a significantly higher elimination rate of postprandial fullness with acotiamide compared to placebo. 125 Only two studies compared the efficacy of acotiamide between PDS and EPS subgroups and found conflicting results. 116, 125 A European trial investigating the long-term safety of acotiamide treatment showed no significant clinical safety concerns. 123 Commonly reported adverse events include diarrhoea, headache and an increase in prolactin levels.
| Neuromodulators
With increasing insight into the pathophysiology of FGIDs over the last decades, the brain-gut-axis is now acknowledged to play a role in the aetiology of FD. As implicated by the name, the brain-gut-axis is a bidirectional communication pathway between the brain and the gut, connecting the central nervous system and the enteric nervous system. 126 Neuromodulators, such as antidepressants and anxiolytics, are often used in low doses to treat refractory FD symptoms through their pain-modulating properties at various levels of the brain-gut axis ( Figure 1) . 126, 127 Moreover, FGID patients often suffer from psychiatric comorbidities such as depression or anxiety disorders, for which neuromodulators are also indicated. 5 Several types of antidepressants have been used for the treatment of FD, including tricyclic antidepressants, tetracyclic antidepressants, serotonin and norepinephrine reuptake inhibitor (SNRIs) and selective serotonin reuptake inhibitors (SSRIs). The therapeutic response of these compounds and the development of side effects varies between agents and between individuals. 128 Despite their reasonably widespread use in clinical settings, 128 and their proven efficacy in IBS, 129 clinical trials investigating the effects of neuromodulators in FD are limited. Table 4 provides an overview of all referenced studies concerning the efficacy of antidepressant agents in FD patients.
The best-studied tricyclic antidepressant in FD is amitriptyline.
Studies showed that amitriptyline improves FD symptoms, especially in EPS patients, but has no significant effect on gastric function. 127, 130, 131 In the largest trial investigating the effects of amitriptyline in FD, 292FD patients were treated for 10 weeks with 50 mg amitriptyline, 10 mg escitalopram, an SSRI, or placebo, and followed up for 6 months. Adequate symptom relief was reached in 53% of the patients following amitriptyline, compared to 40% for placebo and 38% for escitalopram. Moreover, they reported amitriptyline to be superior to placebo and escitalopram in the ulcerlike FD subgroup, now recognised as EPS, but not in the dysmotilitylike FD patients, now considered PDS. 131 The higher rate of symptom relief with tricyclic antidepressants can be explained by their actions on multiple (two or more) neurotransmitter systems, compared to the single affinity of for example SSRI's. On the other side, this characteristic makes tricyclic antidepressants more prone to side effects, including drowsiness, dizziness and suicidal thoughts. 126 Amitriptyline treatment did not affect gastric emptying rate and maximum tolerate volume during a drinking test in FD patients. 131 Hence, its exact mechanism of action remains incompletely elucidated. 133 In an open label study, significant weight regain was observed following mirtazapine treatment in FD patients with weight loss. 134 The exact mechanism of action is incompletely understood. A mechanistic study in 31 healthy subjects reported no effects of mirtazapine (15 mg once daily for 3 weeks) on gastric compliance, sensitivity, accommodation and nutrient tolerance. 135 However, one study showed that mirtazapine upregulates the levels of orexigenic hormones and downregulates the levels of anorexigenic hormones. Therefore, the authors hypothesised that mirtazapine exerts its function through regulating the brain-gut axis and correlation early satiation and gastric emptying half time ↓ in early satiation and ↑ in gastric emptying rate after buspirone (P = 0.001) ↓ in postprandial fullness after amitriptyline (P = 0.046) no effect of clebopride not reported Miwa 140 
T A B L E 4 Efficacy and reported (serious) adverse events ((S)AEs) / adverse reactions (ARs) of neuromodulators to treat functional dyspepsia

Efficacy
FD patients (n = 144) tandospirone 10 mg three times a day 4 wk placebo ↓ upper abdominal pain and discomfort after tandospirone ⇔ placebo (P < 0.02) ↑ proportion of responders in tandospirone group after 3 and 4 wks (P < 0.002 for both) improvement in statetrait anxiety inventory scores in both arms no SAEs reported gastrointestinal hormone levels. 134 However, this is only speculative and more large-scale randomised controlled mechanistic trials are needed to confirm this hypothesis.
Regarding SNRIs, only venlafaxine has been studied in one large (n = 160) randomised placebo-controlled trial in FD, which failed to show efficacy. 136 The dose used in this study was, however, low and varied within the 8-week treatment period (75 mg for FD. 137 Due to their isolated serotonergic effects, SSRIs may be more indicated in psychiatric disorders rather than GI disorders. 126 Lastly, buspirone, a serotonin 1A receptor (5-HT 1A ) agonist with anxiolytic properties, was shown to improve gastric accommodation and GI symptoms in FD patients. 138, 139 Tandospirone, another 5-HT 1A agonist, was superior to placebo in eliminating FD symptoms in a 4-week multi-centre study in Japan. 140 
| Phytotherapy
Herbal preparations, also called phytotherapy, have been used for decades to treat gastrointestinal complaints. Due to the unsatisfactory efficacy, lack of availability or high chances of side effects of the majority of standard therapies for FD, research on phytomedical treatment has increased over the last few years. The major benefit of phytomedical drugs is that they are often better tolerated and can have a broader range of pharmacological effects compared to synthetic drugs which most often target a single receptor or a single mechanism. 141 Table 5 provides an overview of trials investigating the efficacy and safety of phytomedical agents.
An example of an herbal preparation used in the treatment of FD is peppermint oil. Peppermint oil is an extract of fresh leaves of peppermint, Mentha piperita L., and has Ca 2+ antagonistic properties, resulting in relaxation of the GI smooth muscles. 142 Thus far, effects on upper gastrointestinal function have only been investigated in healthy subjects. It has been shown that peppermint oil decreases intragastric pressure and gastroduodenal motility after acute intake. 142, 143 However, no effects were found on the gastric accommodation reflex and gastric emptying rate. of PDS patients and 72% of EPS patients compared to 50% and 40% in the control groups, respectively. 146 Mechanistic studies in patients to elucidate the mechanism of action of peppermint oil are lacking.
A few studies focused on the effects of ginger in FD. It was shown that ginger accelerates gastric emptying compared to placebo, however, no symptom improvement was seen in FD patients after acute ginger administration. 148, 149 No notable adverse events have been reported. Data on symptomatic effects after long-term treatment with ginger are lacking.
FD is a heterogeneous condition with diverse symptom patterns and multiple underlying pathophysiological mechanisms involved.
Therefore, combining several compounds in a herbal preparation can be an advantageous approach to combine their pharmacological actions. Rikkunshito is such a herbal preparation consisting of several constituents. It is marketed in Japan and has been shown to induce a decrease in abdominal pain, heartburn and abdominal distention scores after 2 weeks of treatment. 150 Two large placebo-controlled trials were conducted to evaluate the efficacy and safety of Rikkunshito. In both studies, the Kampo medicine induced a stronger decrease in FD symptoms compared to placebo, especially for PDS symptoms. 151, 152 The Japanese DREAM study reported an incidence of 29.5% of improvement and 8.2% of extreme improvement on overall treatment efficacy after 8 weeks of Rikkunshito treatment, compared to 21.1% and 1.8% after placebo. Moreover, scores for postprandial fullness, early satiation, bloating and anxiety decreased significantly upon Rikkunshito treatment. 152 A follow-up analysis of the trial of Suzuki et al indicated that symptom response was associated with low baseline des-acyl ghrelin levels, abstinence of alcohol and positive H Pylori status. 151, 153 Rikkunshito has been shown to improve gastric function. 150 One of the suggested mechanisms of action is an increase in ghrelin release and a decreased inactivation of ghrelin.
Lastly, iberogast (STW5) has been used for more than 50 years in the treatment of FGIDs. This product contains extracts of nine different plants that act together to regulate gastrointestinal motility and secretion aiming to address overlapping gastrointestinal symptoms. 154 It has been suggested that the different components of iberogast exert their function through 5-HT 4 -receptors, and to a lesser extent though muscarinic and opioid receptors. 155 In vitro and in vivo studies demonstrated that iberogast induces relaxation of the gastric fundus and an increase in antral motility, which can explain its therapeutic effect. 156, 157 No effects on gastric emptying were observed. 157, 158 Randomised, placebo-controlled trials investigating the efficacy and safety of iberogast reported a significantly stronger improvement in FD symptoms compared to placebo, with therapeutic effects noted starting from 2 weeks of treatment. Iberogast was considered to be well-tolerated and safe.
159,160
T A B L E 5 Efficacy and reported (serious) adverse events ((S)AEs) / adverse reactions (ARs) of phytomedical agents to treat FD 161 In a retrospective analysis, the same research group
showed that the superiority of manual acupuncture over shamacupuncture and itopride treatment was only present in the PDS subgroup and not in the EPS subgroup. 162 Furthermore, 2 weeks of transcutaneous electroacupuncture (TEA) treatment twice daily decreased FD symptom scores by 55%, which was significantly more than after placebo or sham-TEA treatment. 163 A study in healthy subjects showed that TEA improved impaired gastric accommodation induced by a cold liquid meal, 164 but this effect has never been investigated in FD patients. Lastly, authentic electroacupuncture for 4 weeks was shown to be superior to sham electroacupuncture, with 62% of the patients reported adequate symptom relief compared to 22% in the sham group. 165 Besides as monotherapy, acupuncture treatment can also be used as add-on therapy, mostly combined with prokinetic agents or PPIs, depending on FD subtype. The combination of acupuncture and drug therapy improved gastrointestinal and psychological symptoms more than conventional treatment alone, and these effects last longer. 166, 167 A recent meta-analysis comparing several combinations of acupuncture and conventional therapy revealed that treatment with clebopride, an older prokinetic agent with limited availability, complemented with acupuncture has the highest probability for symptom relief in FD patients. 168 Putatively, the improvement in symptoms is related to the acceleration of gastric emptying or the altered brain connectivity and normalisation of brain-gut-axis function following acupuncture in FD. 169, 170 However, both mechanisms have only been tested in a few small studies, so more large-scale studies are needed to further elucidate these options. A Chinese study investigating the adverse events related to acupuncture reported adverse events in only 3.76% of the patients undergoing acupuncture for migraine, FD or Bell's palsy. All side effects were temporary, indicating that acupuncture is a safe technique to treat FD. (Table 6 ). Recent research showed that adding psychotherapy to standard medical therapy yielded more favourable effects on FD symptoms and quality of life compared to medical treatment alone. 172, 173 When standardised symptom-oriented medical therapy was compared with intensified medical management, focusing on motor and sensory function abnormalities, with or without psychological interventions (progressive-muscle relaxation or cognitive behavioural therapy), greater symptom improvement was reported after intensive medical treatment with or without psychological therapy. Furthermore, the combination of intensive medical treatment and cognitive behavioural therapy was superior to standard medical treatment in improving concomitant anxiety and depression. 174 Compared to IBS, FD has received little attention in hypnotherapy research. In one study performed by Calvert et al, improvement
in GI symptoms and quality of life was reported in 59% of the patients following weekly hypnotherapy sessions for 3 months, compared to 41% receiving conventional medical treatment and 34% receiving supportive therapy. At one-year follow-up, none of the patients who followed hypnotherapy required medical treatment, compared to 82% and 90% of patients in the supportive and conventional groups, respectively. 175 In addition, gut-oriented hypnotherapy also proved to be efficient in the treatment of FD by reducing gastric emptying time. 176 Notably, also for patients without clinically significant psychological comorbidity, psychological interventions, such as gut-oriented hypnosis, and cognitive behavioural therapy, decrease the need for health care utilisation. This study showed greater flexibility in coping and greater reduction in FD symptoms following flexible coping psychotherapy compared to supportive therapy. 178 Based on these satisfactory effects of psychotherapy on FD, it could be suggested to implement it relatively early in the treatment of FD to increase symptom reduction and accelerate symptom relief.
However, availability of skilled and motivated therapists and reimbursement issues are major hurdles to larger scale use of psychological therapies. ↑ symptom improvement after hypnotherapy ⇔ supportive therapy (P = 0.06) and medical therapy (P = 0.01) after 16 wks ↑ long-term improvement after hypnotherapy ⇔ supportive therapy (P < 0.02) and medical therapy (P < 0.01) ↑ quality of life after hypnotherapy ⇔ supportive therapy (short-term: P < 0.01) and medical therapy (short and long-term: P < 0.01) ↓ in anxiety after hypnotherapy and supportive therapy (P < 0. suggested that prokinetic agents would be more efficient for PDS and acid suppressive therapy for EPS, but research showed inconsistent results. This is at least in part due to the large overlap between EPS and PDS in the Rome III consensus, which is reduced under the Rome IV consensus. 182 However, for many of the therapeutic approaches, superiority in one of both FD subgroups has never been investigated, and studies addressing efficacy in FD subgroups according to the Rome IV subdivision are lacking. Of note, within each subgroup, a certain pathophysiological mechanism can only be detected in a subset of patients. Consequently, it could be worthwhile to consider a subdivision based on underlying pathophysiology or impaired functions rather than symptoms to determine treatment strategy. In this line of thought, large-scale trials focusing on individualised treatment based on established pathophysiology should elucidate whether this subdivision yields better results regarding efficacy of treatment. A prerequisite for this approach is availability of reliable and acceptable tests or features to identify underlying pathophysiological mechanisms, and this has not been realised to date.
| DISCUSSION
Secondly, the relationship between improvement of gastric function and symptom reduction remains controversial, especially for delayed gastric emptying, again highlighting the complexity of FD. 51 This relationship or lack thereof is less well-investigated for other frequently impaired gastric functions in FD such as gastric hypersensitivity or impaired accommodation. Furthermore, for many pharmacological treatment options, the exact mechanism of action is not completely understood. Consequently, no specific mechanism, enzyme or receptor can be identified to be targeted when developing new drugs. Additionally, as mentioned above, the best-studied pathophysiological abnormalities (impaired gastric accommodation, delayed gastric emptying and hypersensitivity to distention) are only present in a subset of patients. 183 How to explain the symptoms in the remaining patients is still unknown. Putatively, pathophysiological mechanisms yet to be discovered explain the gaps in our current pathophysiological concepts. A recent addition to the pathophysiological concepts in FD is low-grade duodenal inflammation with increased eosinophil counts, 184, 185 but studies targeting this abnormality in adult FD are currently lacking. In addition, a preliminary report suggests that FD patients may have altered duodenal microbiota composition. 186 In favour of a potential role for intestinal microbiota in the pathogenesis of FD are the occurrence of post-infectious FD and a single report of a response to treatment with the non-absorbable antibiotic rifaximin. 187, 188 More research on the pathophysiology of FD as well as interventional studies are needed to elucidate these aspects.
Based on its prevalence, impact and associated unmet need, FD would be expected to represent an attractive drug development target for pharmaceutical companies. However, the lack of an existing regulatory track (except for the approval of acotiamide in Japan), the focus on the closely related entity of (idiopathic) gastroparesis as well as the lack of validated patient-reported outcome (PRO) measures have been major impediments to new drug development for FD. 189 The latter issue may be solved with development of PROs for FD both in Europe and in the USA. 
